Clinical data | |
---|---|
Trade names | Alone: Ergomar, others With caffeine: Cafergot, others |
Other names | 2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione |
AHFS/Drugs.com | Monograph |
Routes of administration | By mouth, under the tongue[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Intravenous: 100%,[2] Intramuscular: 47%,[3] By mouth: <1%[4] (Enhanced by co-administration of caffeine[2]) |
Metabolism | Liver[3] |
Elimination half-life | 2 hours[3] |
Excretion | 90% biliary[3] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C33H35N5O5 |
Molar mass | 581.673 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ergotamine, sold under the brand names Ergomar among others, is a medication used to treat migraines, cluster headaches, and post partum bleeding.[1][6] It is not effective for tension headaches.[1] It is taken by mouth, under the tongue, or rectally.[1][7] Onset of effects is generally between 30 minutes and 2 hours.[8]
Common side effects include nausea, abdominal pain, and tingling extremities.[1] Other side effects may include medication overuse headaches, pulmonary fibrosis, and ergotism.[9][1] Use in pregnancy or when breastfeeding may harm the baby.[5] It is not recommended in people with vascular disease, liver, or kidney problems.[9] It is in the ergot family of medications and acts on serotonin among other receptors.[9][8]
Ergotamine was first isolated by Arthur Stoll in 1918 from ergot fungus.[10] The fungus had been used medicinally since at least the 16th century to induce childbirth, treat bleeding after childbirth, or bring about an abortion.[11] In the United States it is generally only used if triptans are not effective; though remains commonly used in some parts of the world.[9] It is also available with caffeine under the brand Cafergot among others.[1]
References
edit- ^ a b c d e f g h i j "Ergotamine Monograph for Professionals". Drugs.com. Archived from the original on 27 January 2021. Retrieved 23 July 2021.
- ^ a b Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–4. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.
- ^ a b c d Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". In Olesen J, Tfelt-Hansen P, Welch KM (eds.). The Headaches. New York: Raven Press. pp. 313–22.
- ^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–9. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.
- ^ a b "Ergotamine (Ergomar) Use During Pregnancy". Drugs.com. Archived from the original on 25 November 2020. Retrieved 23 July 2021.
- ^ Weeks, A (January 2015). "The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?". BJOG : An International Journal of Obstetrics and Gynaecology. 122 (2): 202–10. doi:10.1111/1471-0528.13098. PMID 25289730.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 500. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ a b Aschenbrenner, Diane S.; Venable, Samantha J. (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. p. 423. ISBN 978-0-7817-6587-9. Archived from the original on 2021-08-28. Retrieved 2021-07-23.
- ^ a b c d Levin, Morris (8 May 2008). Comprehensive Review of Headache Medicine. Oxford University Press, USA. p. 217. ISBN 978-0-19-536673-0. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
- ^ Silberstein, Stephen D. (8 May 2018). Headache in Clinical Practice. Routledge. p. PT19. ISBN 978-1-351-44131-5. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
- ^ Nielsch, Ulrich; Fuhrmann, Ulrike; Jaroch, Stefan (30 March 2016). New Approaches to Drug Discovery. Springer. p. PA6. ISBN 978-3-319-28914-4. Archived from the original on 28 August 2021. Retrieved 23 July 2021.